PTRH2: A Potential Drug Target and Biomarker for Various Diseases

Target Name: PTRH2

NCBI ID: G51651

PTRH2

PTRH2: A Potential Drug Target and Biomarker for Various Diseases

Protoplasmic reticulum-associated protein 2 (PTRH2) is a protein that is expressed in various tissues throughout the body. It is a member of the cytoskeletal protein family and is involved in the structure and function of the endoplasmic reticulum (ER). PTRH2 is also Known as CFAP37 and has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

PTRH2 functions as a negative regulator of the microtubules of the ER, which are essential for the transport of various cellular processes, including protein synthesis and import. The ER is a highly dynamic structure that is constantly in flux, and PTRH2 plays a critical role in Maintain the stability and integrity of the ER cytoskeleton.

Expression and localization

PTRH2 is expressed in a variety of tissues, including muscle, heart, brain, and cancer. It is primarily expressed in the ER and is also found in the cytoplasm. PTRH2 is a 21-kDa protein that has a calculated molecular mass of 32.1 kDa . It has a distinct N-terminus that is involved in the ER cytoskeleton and a C-terminus that is involved in the cytoskeleton.

PTRH2 is localized to the ER in a subcellular distribution, and its localization is regulated by various factors, including its own size, the size of its associated chaperone protein, and the local conditions in the ER. PTRH2 has been shown to form a complex with the chaperone protein APC1 (伪-actinin-1) in the ER, and this complex has been shown to play a role in regulating the ER cytoskeleton.

Drug targeting

PTRH2 has been identified as a potential drug target due to its involvement in the ER cytoskeleton and its role in various diseases. One of the main drug targets for PTRH2 is the inhibition of its activity, which can lead to the relaxation of the ER cytoskeleton and the disruption of its function.

PTRH2 has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, PTRH2 has been shown to be involved in the development and progression of colon cancer. Studies have shown that inhibition of PTRH2 can lead to the inhibition of the growth and migration of cancer cells, making it a potential therapeutic approach for cancer treatment.

Another potential drug target for PTRH2 is the inhibition of its function in neurodegenerative diseases, such as Alzheimer's disease. PTRH2 has been shown to be involved in the regulation of the neurotransmitter excitotoxicity, which is a hallmark of neurodegenerative diseases. The inhibition of PTRH2 activity has has been shown to protect against neurotoxicity in models of Alzheimer's disease.

In addition to its potential drug targets, PTRH2 has also been identified as a potential biomarker for various diseases. The PTRH2 protein has been shown to be involved in the regulation of cellular processes, including cell adhesion, migration, and invasion. Therefore, its levels may be a potential indicator of disease severity or the effectiveness of a given treatment.

Conclusion

PTRH2 is a protein that is involved in the regulation of various cellular processes, including the ER cytoskeleton and the regulation of cellular processes. Its localization to the ER and its involvement in the regulation of the ER cytoskeleton make it a potential drug target for various diseases , including cancer, neurodegenerative diseases, and autoimmune disorders. The inhibition of PTRH2 activity has been shown to lead to the disruption of its function

Protein Name: Peptidyl-tRNA Hydrolase 2

Functions: The natural substrate for this enzyme may be peptidyl-tRNAs which drop off the ribosome during protein synthesis

The "PTRH2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PTRH2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets